Abstract
On January 25, 2022, the U.S. Food and Drug Administ-ration (FDA) approved the use of tebentafusp, a bispecific glycoprotein 100 (gp100) peptide-human......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
